Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia
TO THE EDITOR:
Related Articles
Tarlatamab Earns UK Approval for Previously Treated ES-SCLC
Tarlatamab was granted conditional marketing authorization in the United Kingdom for previously treated extensive-stage small cell lung cancer.
Treatment of Pleural Mesothelioma: ASCO Guideline Update
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the…
LOTIS-5 Trial of Lonca-R Completes Enrollment in R/R DLBCL
Enrollment in the LOTIS-5 trial of loncastuximab tesirine-lpyl with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma has been completed.
Nivolumab Plus Ipilimumab Wins European Approval for MSI-H/dMMR mCRC
Nivolumab plus ipilimumab has been approved in Europe for the frontline treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer.
Understanding the experience of Latinas in medical education: A qualitative study
Despite improvements in recruitment of Latina medical students, the percentage of Latina physicians has remained stagnant, suggesting unique barriers to retention and career advancement. This…
Paying It Forward: The Importance of Mentorship in a Medical Career
Beyond a lengthy list of accomplishments across the leukemia spectrum of treatment, Garcia-Manero holds the importance of mentorship as incredibly dear to his heart and…
Mobile Internet-Based Postop Management Enhanced Patient Experience After Radical Prostatectomy – Oncology Nurse Advisor
Researchers conducted a retrospective study to determine the effectiveness of internet-based postop care for patients with prostate cancer.
Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy
Colorectal cancer (CRC) remains a major global health burden, being one of the most prevalent cancers with high mortality rates. Despite advances in conventional treatment…
‘Increased survival rates’ for bladder cancer patients given immunotherapy drug
Experts said Durvalumab could be a ‘game changer’.
Stressing the importance of circadian time in treatment responses
Circadian disruption increases cancer risk, but connections between circadian clocks and cancer biology are diverse and depend on tumor type. In this issue of Cancer…
